Matching articles for "tisagenlecleucel"
In Brief: Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • June 26, 2023; (Issue 1679)
The FDA has approved lisocabtagene maraleucel
(Breyanzi – BMS) for treatment of adults with large
B-cell lymphoma (LBCL), including diffuse large
B-cell lymphoma (DLBCL) not otherwise...
The FDA has approved lisocabtagene maraleucel
(Breyanzi – BMS) for treatment of adults with large
B-cell lymphoma (LBCL), including diffuse large
B-cell lymphoma (DLBCL) not otherwise specified,
high-grade B-cell lymphoma, primary mediastinal
large B-cell lymphoma, or follicular lymphoma
grade 3B who have disease refractory to first-line
chemoimmunotherapy, relapsed within 12 months
of or after first-line chemoimmunotherapy, are not
eligible for hematopoietic stem cell transplantation
due to comorbidities or age, or have relapsed
or refractory disease after ≥2 lines of systemic
therapy. Breyanzi is an individualized cellular
product prepared from the patient's own T cells,
which are genetically modified to express chimeric
antigen receptors (CAR) and then infused back into
the patient. The CAR T-cell products axicabtagene
ciloleucel (Yescarta) and tisagenlecleucel (Kymriah)
are also FDA-approved for treatment of large B-cell
lymphoma.
In Brief: Brexucabtagene autoleucel (Tecartus) for Acute Lymphoblastic Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • June 12, 2023; (Issue 1678)
Brexucabtagene autoleucel (Tecartus – Kite) has
been approved by the FDA for treatment of adults
with relapsed or refractory B-cell precursor acute
lymphoblastic leukemia (ALL). It was previously
approved...
Brexucabtagene autoleucel (Tecartus – Kite) has
been approved by the FDA for treatment of adults
with relapsed or refractory B-cell precursor acute
lymphoblastic leukemia (ALL). It was previously
approved for treatment of relapsed or refractory
mantle cell lymphoma. Tecartus is an individualized
cellular product prepared from the patients own
T cells, which are genetically modified to express
chimeric antigen receptors (CAR) and then infused
back into the patient. The CAR T-cell immunotherapy
tisagenlecleucel (Kymriah) was approved in 2017 for
treatment of relapsed or refractory B-cell precursor
ALL in patients ≤25 years old.
Mosunetuzumab (Lunsumio) for Follicular Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • March 6, 2023; (Issue 1671)
Mosunetuzumab-axgb (Lunsumio – Genentech),
a bispecific CD20-directed CD3 T-cell engager,
has received accelerated approval from the FDA
for treatment of relapsed or refractory follicular
lymphoma in...
Mosunetuzumab-axgb (Lunsumio – Genentech),
a bispecific CD20-directed CD3 T-cell engager,
has received accelerated approval from the FDA
for treatment of relapsed or refractory follicular
lymphoma in adults who received ≥2 lines of systemic
therapy. It is the first T-cell-engaging bispecific
antibody to be approved in the US for this indication.
Axicabtagene Ciloleucel (Yescarta) for B-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • July 16, 2018; (Issue 1551)
The FDA has approved axicabtagene ciloleucel
(Yescarta – Kite) for treatment of adults with relapsed
or refractory CD19+ large B-cell lymphoma after ≥2
lines of systemic therapy. Yescarta is an...
The FDA has approved axicabtagene ciloleucel
(Yescarta – Kite) for treatment of adults with relapsed
or refractory CD19+ large B-cell lymphoma after ≥2
lines of systemic therapy. Yescarta is an individualized
cellular product prepared from the patient's own T cells,
which are genetically modified to express chimeric
antigen receptors (CAR) and then infused back into
the patient. It is the second CAR T-cell immunotherapy
to become available in the US. Tisagenlecleucel
(Kymriah), a CAR T-cell product previously approved
for treatment of relapsed or refractory B-cell precursor
acute lymphoblastic leukemia (ALL) in patients ≤25
years old, was recently also approved for relapsed or
refractory CD19+ large B-cell lymphoma after ≥2 lines
of systemic therapy.
Inotuzumab Ozogamicin (Besponsa) - An Antibody-Drug Conjugate for ALL (online only)
The Medical Letter on Drugs and Therapeutics • May 21, 2018; (Issue 1547)
The FDA has approved inotuzumab ozogamicin
(Besponsa – Pfizer), a humanized anti-CD22
monoclonal antibody conjugated to the cytotoxic
antibiotic calicheamicin, for treatment of relapsed
or refractory...
The FDA has approved inotuzumab ozogamicin
(Besponsa – Pfizer), a humanized anti-CD22
monoclonal antibody conjugated to the cytotoxic
antibiotic calicheamicin, for treatment of relapsed
or refractory B-cell precursor acute lymphoblastic
leukemia (ALL) in adults. It is the first CD22-directed
antibody-drug conjugate to be approved in the US.
Tisagenlecleucel (Kymriah) for ALL
The Medical Letter on Drugs and Therapeutics • October 23, 2017; (Issue 1532)
The FDA has approved tisagenlecleucel (Kymriah —
Novartis), an individualized, genetically-modified
cellular product, for treatment of relapsed or refractory
B-cell precursor acute lymphoblastic leukemia...
The FDA has approved tisagenlecleucel (Kymriah —
Novartis), an individualized, genetically-modified
cellular product, for treatment of relapsed or refractory
B-cell precursor acute lymphoblastic leukemia (ALL)
in patients ≤25 years old. The patient's own T cells
are genetically modified to express chimeric antigen
receptors (CAR) and then reinfused. Kymriah is the
first CAR T-cell immunotherapy to become available in
the US. A CAR T-cell product for B-cell non-Hodgkin's
lymphoma is expected to be approved soon.